1.Composite liver tumors: A radiologic-pathologic correlation.
Megha NAYYAR ; David K IMAGAWA ; Temel TIRKES ; Aram N DEMIRJIAN ; Roozbeh HOUSHYAR ; Kumar SANDRASEGARAN ; Chaitali S NANGIA ; Tara SEERY ; P BHARGAVA ; Joon II CHOI ; Chandana LALL
Clinical and Molecular Hepatology 2014;20(4):406-410
Bi-phenotypic neoplasm refers to tumors derived from a common cancer stem cell with unique capability to differentiate histologically into two distinct tumor types. Bi-phenotypic hepatocellular carcinoma-cholangiocarcinoma (HCC-CC), although a rare tumor, is important for clinicians to recognize, since treatment options targeting both elements of the tumor are crucial. Imaging findings of bi-phenotypic HCC-CC are not specific and include features of both HCC and CC. A combination of imaging and immuno-histochemical analysis is usually needed to make the diagnosis.
CA-19-9 Antigen/metabolism
;
Carcinoma, Hepatocellular/mortality/pathology/radiography
;
Cholangiocarcinoma/mortality/pathology/radiography
;
Humans
;
Liver Neoplasms/mortality/pathology/*radiography
;
Magnetic Resonance Imaging
;
Phenotype
;
Risk Factors
;
Survival Analysis
;
Tomography, X-Ray Computed
;
alpha-Fetoproteins/analysis
2.Non-Spine Bone Metastasis as an Initial Manifestation of Cancer in Korea.
Wanlim KIM ; Ilkyu HAN ; Seungcheol KANG ; Sang A LEE ; Han Soo KIM
Journal of Korean Medical Science 2014;29(3):357-362
Non-spine bone metastasis accounts for approximately 20% of all skeletal metastases, but little data have been published that focused on bone metastasis to the pelvis and extremities as an initial manifestation of cancer. We determined 1) clinicopathologic characteristics of patients who presented with non-spine bone metastasis of unknown primary malignancy, and 2) process by which the diagnosis of primary cancer was made. We retrospectively reviewed 84 patients with bone metastasis of unknown primary cancer site at the time of presentation. The study population consisted of 56 men and 28 women, with a mean age of 59.1 yr (17.5-85.6 yr). The average follow-up period was 20.8 months (1-120 mo). Primary cancer site was identified in 79 patients (94.0%), and was determined to be the lung (46.4%), kidney (13.1%), liver (9.5%), thyroid (8.3%), and prostate (4.8%). Five-year overall survival rate was 28.0%. Multiple bone metastases, distant organ metastasis, and multiple bone with organ metastases were the significant prognostic factors in univariate analysis. Multiple bone metastases remained significant after multivariate analysis (P = 0.008). Lung cancer is the most common site of primary cancer, and patients with multiple bone metastases have a poor prognosis, possibly due to disseminated cancer and a greater tumor burden.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Bone Neoplasms/mortality/pathology/*secondary
;
Female
;
Follow-Up Studies
;
Humans
;
Kidney Neoplasms/pathology
;
Liver Neoplasms/pathology
;
Lung Neoplasms/pathology/radiography
;
Male
;
Middle Aged
;
Prognosis
;
Prostatic Neoplasms/pathology
;
Republic of Korea
;
Retrospective Studies
;
Survival Rate
;
Thyroid Neoplasms/pathology
;
Young Adult
3.CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers.
Wei Fu LV ; Jian Kui HAN ; De Lei CHENG ; Chun Ze ZHOU ; Ming NI ; Dong LU
Korean Journal of Radiology 2015;16(4):810-820
OBJECTIVE: To prospectively evaluate the performance of computed tomography perfusion imaging (CTPI) in predicting the early response to transarterial chemo-lipiodol infusion (TACLI) and survival of patients with colorectal cancer liver metastases (CRLM). MATERIALS AND METHODS: Computed tomography perfusion imaging was performed before and 1 month after TACLI in 61 consecutive patients. Therapeutic response was evaluated on CT scans 1 month and 4 months after TACLI; the patients were classified as responders and non-responders based on 4-month CT scans after TACLI. The percentage change of CTPI parameters of target lesions were compared between responders and non-responders at 1 month after TACLI. The optimal parameter and cutoff value were determined. The patients were divided into 2 subgroups according to the cutoff value. The log-rank test was used to compare the survival rates of the 2 subgroups. RESULTS: Four-month images were obtained from 58 patients, of which 39.7% were responders and 60.3% were non-responders. The percentage change in hepatic arterial perfusion (HAP) 1 month after TACLI was the optimal predicting parameter (p = 0.003). The best cut-off value was -21.5% and patients who exhibited a > or = 21.5% decrease in HAP had a significantly higher overall survival rate than those who exhibited a < 21.5% decrease (p < 0.001). CONCLUSION: Computed tomography perfusion imaging can predict the early response to TACLI and survival of patients with CRLM. The percentage change in HAP after TACLI with a cutoff value of -21.5% is the optimal predictor.
Adult
;
Aged
;
Colorectal Neoplasms/mortality/*pathology
;
Contrast Media/administration & dosage
;
Ethiodized Oil/*administration & dosage
;
Female
;
Hepatic Artery/radiography
;
Humans
;
Liver Neoplasms/*drug therapy/mortality/*radiography/secondary
;
Male
;
Middle Aged
;
Perfusion Imaging/*methods
;
Prospective Studies
;
Survival Rate
;
Tomography, X-Ray Computed/methods